Core Viewpoint - AB Science has reached an agreement in principle with its financial creditors to postpone the repayment of its bank debt by 24 months, contingent upon the postponement of a loan repayment with the EIB by at least 12 months [2][7]. Group 1: Loan Repayment Terms - The total amount of bank debt to be postponed is approximately 3.7 million euros, with the agreement conditional on a 12-month delay for a 12 million euro loan from the EIB, originally due in January and December 2028 [2][4]. - The restructuring terms include state-guaranteed loans (PGE) with a balance of 3.5 million euros [3]. - A freeze on principal repayments is set from January 1, 2025, to December 31, 2026, with amortization resuming on January 1, 2027 [8]. Group 2: Financial Strategy - Savings from the postponed repayments will be invested in research and development [7]. - The EIB loan is structured in two tranches of 6 million euros each, with specific maturity dates in 2028 [4]. - An innovation loan with a balance of 0.2 million euros will also have a freeze on principal repayments from January 1, 2025, to September 30, 2025, with amortization resuming on October 1, 2025 [8]. Group 3: Company Overview - AB Science, founded in 2001, specializes in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [5][6]. - The company's lead compound, masitinib, is already registered for veterinary use and is being developed for human medicine across various disease areas [6].